IRCT201211124365N15 IRCT 2012-12-15 Vice chancellor for research of Mazandaran University of Medical Sciences Determination of optimal prophylactic dose of magnesium sulfate for prevention of atrial fibrillation after CABG surgery Determination of optimal prophylactic dose of magnesium sulfate for prevention of atrial fibrillation after CABG surgery 2011-05-22 anticipated 120 Complete https://irct.ir/trial/4662 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention. 2-3 Atrial fibrillation. Intervention 1: Intervention 1: 60 mg/Kg MgSO4 via cardioplegic solution during cross clamping. Intervention 2: Intervention 2: 80 mg/Kg MgSO4 via cardioplegic solution during cross clamping. Intervention 3: Intervention 3: 100mg/Kg MgSO4 via cardioplegic solution during cross clamping.

public Afshin Gholipour Baradari, MD

Moallem Square, Mazandaran University of Medical Sciences

Sari Iran (Islamic Republic of) 48175-866 +98 15 1222 6262 gholipourafshin@mazums.ac.ir; gholipourafshin@yahoo.com Mazandaran University of Medical Sciences scientific Rahman Ghafari MD

Moallem Square, Mazandaran University of Medical Sciences

Sari Iran (Islamic Republic of) +98 15 1222 6262 drghafari@yahoo.com Mazandaran University Of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: signing informed consent; candidate for elective CABG based on angiography; use of cardiopulmonary bypass (CBP) during surgery; no previous history of any cardiac dysrhythmias that is under treatment ( including AF); hemodynamic stability ( MAP>50, heart rate between 50-110); age between 35&75 years old. Exclusion criteria: history of heart failure (Ejection Fraction less than 30%); more than 4 grafts; renal failure ( serum creatinine >1.5 in two consecutive test); hepatic failure ( liver function tests more than 1.5 times of normal value); history of COPD; hyperthyroidism; serum PH < 7.25 or > 7.55; postoperative MI; second or third degree AV block; need for pacemaker after surgery; reoperation for any reason; history of pervious cardiac surgery; anti-arrhythmic drugs consumption (except beta blocker). 35 years 75 years Both I48 Atrial fibrillation and flutter Prevention Prevention Prevention Intervention 1: 60 mg/Kg MgSO4 via cardioplegic solution during cross clamping Intervention 2: 80 mg/Kg MgSO4 via cardioplegic solution during cross clamping Intervention 3: 100mg/Kg MgSO4 via cardioplegic solution during cross clamping Atrial fibrillation. Timepoint: up to 3 days after operation. Method of measurement: ECG monitoring. PH. Timepoint: Before Before trial, during the operation,1st day, 2nd day and 3th day after operation, during the operation,1st day, 2nd day and 3th day after operation. Method of measurement: Laboratory kit. K. Timepoint: Before Before trial, during the operation,1st day, 2nd day and 3th day after operation, during the operation,1st day, 2nd day and 3th day after operation. Method of measurement: Laboratory kit - mEq/L. Mg. Timepoint: Before Before trial, during the operation,1st day, 2nd day and 3th day after operation, during the operation,1st day, 2nd day and 3th day after operation. Method of measurement: Laboratory kit - mg/dl. Vice chancellor for research of Mazandaran University of Medical Sciences Approved 2011-02-05 Ethic committee of Mazandaran University of Medical Sciences Moallem Square, Mazandaran University of Medical Sciences Sari Iran (Islamic Republic of)